- Home
- ESPR vs KALV Comparison
ESPR vs KALV Comparison
Compare ESPR & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- KALV
- Stock Information
- Founded
- ESPR 2008
- KALV N/A
- Country
- ESPR United States
- KALV United States
- Employees
- ESPR N/A
- KALV N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- KALV Health Care
- Exchange
- ESPR Nasdaq
- KALV Nasdaq
- Market Cap
- ESPR 399.0M
- KALV 418.1M
- IPO Year
- ESPR 2013
- KALV N/A
- Fundamental
- Price
- ESPR $2.32
- KALV $8.83
- Analyst Decision
- ESPR Buy
- KALV Strong Buy
- Analyst Count
- ESPR 5
- KALV 6
- Target Price
- ESPR $7.30
- KALV $26.25
- AVG Volume (30 Days)
- ESPR 8.5M
- KALV 392.5K
- Earning Date
- ESPR 11-07-2024
- KALV 12-05-2024
- Dividend Yield
- ESPR N/A
- KALV N/A
- EPS Growth
- ESPR N/A
- KALV N/A
- EPS
- ESPR N/A
- KALV N/A
- Revenue
- ESPR $295,451,000.00
- KALV N/A
- Revenue This Year
- ESPR $186.90
- KALV N/A
- Revenue Next Year
- ESPR $31.10
- KALV N/A
- P/E Ratio
- ESPR N/A
- KALV N/A
- Revenue Growth
- ESPR 187.12
- KALV N/A
- 52 Week Low
- ESPR $1.58
- KALV $7.97
- 52 Week High
- ESPR $3.94
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- ESPR 45.30
- KALV 43.73
- Support Level
- ESPR $2.12
- KALV $7.97
- Resistance Level
- ESPR $2.54
- KALV $8.86
- Average True Range (ATR)
- ESPR 0.33
- KALV 0.59
- MACD
- ESPR -0.09
- KALV 0.04
- Stochastic Oscillator
- ESPR 22.86
- KALV 45.26
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.